Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(11%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
6
67%
Ph not_applicable
1
11%
Ph phase_2
2
22%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(3)

Detailed Status

Completed4
unknown2
Withdrawn1
Suspended1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (66.7%)
Phase 22 (22.2%)
N/A1 (11.1%)

Trials by Status

withdrawn111%
suspended111%
recruiting111%
completed444%
unknown222%

Recent Activity

1 active trials
Showing 5 of 9
suspendedphase_1

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

NCT06741072
recruitingphase_1

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NCT05950139
completedphase_2

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

NCT02802943
withdrawnphase_2

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NCT02754362
completednot_applicable

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06741072Phase 1

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Suspended
NCT05950139Phase 1

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Recruiting
NCT02802943Phase 2

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Completed
NCT02754362Phase 2

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Withdrawn
NCT00694551Not Applicable

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Completed
NCT02429440Phase 1

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Unknown
NCT02452307Phase 1

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Unknown
NCT00471471Phase 1

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed
NCT00845611Phase 1

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9